At the news
? NEUTRALIMPACT 2/10 144 filed Nov 2, 2026 at 17:20 ET
Christine Poon, a director of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 7,830 shares of common stock with an approximate market value of $7.53 million, to be executed through Goldman Sachs. The shares were acquired through stock option exercises in 2018, 2019, and 2020. This is a routine insider sale by a non-executive director and represents a small fraction of the company's $84.3 billion market cap.
- Christine Poon, a director, filed Form 144 to sell 7,830 shares of Regeneron common stock.
- Estimated sale value is approximately $7.53 million based on the filing.
- Shares were acquired via stock option exercises on January 3, 2018, 2019, and 2020 (2,610 shares each).
- The sale is planned for execution on or after November 2, 2026 through Goldman Sachs & Co. LLC.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access